Hans Peng ⎜Aug 2, 2018 ⎜ Industry
Since China was the highlighted country of 2018 SNMMI in Philadelphia, several CSNM board members presented a brief report of 2018 SNMMI to the audience. One interesting fact needs attention is that Lu-177 is the most discussed topic this year not only because Lu-177 is highly in demand during SNMMI, but also more and more professors and doctors in China have realized how important and effective Lu-177 is when it is used to diagnose and treat prostate cancer. (more…)
David T. Drummond ⎜Jun 29, 2018 ⎜ Industry
PHILADELPHIA (Embargoed until 6:30 p.m. EDT, Tuesday, June 26, 2018) – In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), researchers reported on a phase II prospective trial. Using gallium-68 (68Ga)-PSMA11 positron emission tomography (PET) imaging, men who had exhausted conventional therapies were screened. Those with high PSMA-expression proceeded to 177Lu-PSMA617 (LuPSMA) therapy and experienced high response rates, which is clearly demonstrated in the PSMA PET imaging figure selected as the 2018 SNMMI Image of the Year.
Each year, SNMMI chooses an image that exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. The state-of-the-art technologies captured in these images demonstrate the capacity to improve patient care by detecting disease, aiding diagnosis, improving clinical confidence and providing a means of selecting appropriate treatments. This year, the SNMMI Henry N. Wagner, Jr., Image of the Year was chosen from more than 2,200 abstracts submitted to the meeting and voted on by reviewers and the society leadership.
The 2018 Image of the Year goes to a team of researchers at the Peter MacCallum Cancer Centre in Melbourne, Australia. The image demonstrates exceptional responses in a series of patients who received LuPSMA therapy after other treatments stopped working. In each patient, the extent of tumor spread before and after treatment is visualized with clarity using PSMA PET. These patients experienced improved quality of life, including reduction of pain, and correlated with marked reduction of prostate specific antigen (PSA), a blood tumor marker.
“This work reflects an appreciation for all the basic science and translation work that has been performed by many groups over a long period of time to develop prostate-specific membrane antigen (PSMA) theranostics as a paradigm-changing practice for improving patient outcomes,” explained Professor Michael Hofman of the Peter MacCallum Cancer in Melbourne, Australia. “These images tell a story about exceptional responses observed in patients who had progressed after standard therapies. They match striking improvements in patient quality of life. With further research, we look forward to seeing nuclear medicine evolve as a key specialty and standard-of-care in cancer management.” He added, “I would also like to extend thanks to ANSTO, Australia’s producer of no-carrier-added Lutetium-177, and Endocyte, which produces PSMA; they helped make this study possible.”
Umar Mahmood, MD, PhD, chair of the SNMMI Scientific Program Committee, noted, “The last decade has seen a blossoming of theranostics to treat tumors with molecularly-guided radiotherapy. The expansion of patients benefiting from this approach is remarkable, and it is wonderful to know that this effort is being led by nuclear medicine physicians and scientists.”
Mahmood stated, “Prostate cancer, which affects millions of men around the world, can be painful and deadly in the metastatic setting. This phase II prospective study by Michael Hofman and colleagues clearly shows the benefit to men with castrate-resistant prostate cancer treated with a beta emitter targeting PSMA when their tumors expressed PSMA. It is gratifying to see the benefit of the approach both rigorously and objectively demonstrated in this trial, in terms of improvement in disease burden and improvement in the pain severity the men suffered.”
Abstract 531: “High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial,” Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.
David T. Drummond ⎜Jan 19, 2018 ⎜ Calendar
2018 June 23 to 26 @ Pennsylvania Convention Center, Headquarter Hotel: Philadelphia Marriott
isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). You can find us at Booth 1001 in the Pennsylvania Convention Center. We hope to see you there and we can arrange a time and place to meet if you wish.
We look forward to seeing you in Philadelphia, Pennsylvania.
Patricia Acton ⎜Aug 16, 2017 ⎜ Calendar
isoSolutions is pleased to inform you that we will exhibit at the 2017 Western Region Society of Nuclear Medicine Annual Meeting held at the Westin BayShore in Vancouver, British Columbia from 2017–11–03 to 2017–11–05. We hope to see you there and we can arrange a time and place to meet if you wish.
David T. Drummond ⎜Jun 2, 2017 ⎜ Calendar
2017 June 10 to 14 @ The Colorado Convention Center, 700 14th St, Denver, CO 80202
isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). You can find us at Booth 931 in the Colorado Convention Center. We hope to see you there and we can arrange a time and place to meet if you wish.
We look forward to seeing you in Denver, Colorado.
David T. Drummond ⎜Jun 1, 2016 ⎜ Calendar
The annual meeting of the Society of Nuclear Medicine and Medical Imaging (SNNMI) will be held in Vancouver, Canada from 08 June to 12 June 2013. isoSolutions Marketing & Management Inc. will be exhibiting a wide range of nuclear medicine products.
isoSolutions is presenting a package of products and services for diagnostic and therapeutic radiolabeling applications — a complete labeling solution. isoSolutions can provide a complete range of radioisotopes, including a Ga-68 Generator (iThemba), Lu-177, Y-90, Re-188 and I-131. These products are complemented by a state-of-the-art automated labeling module (Trasis All-in-One) and a complete range of labeling peptides. Finally, expert, experienced consulting services are offered for radiochemistry, licensing (preparation of CMC sections, INDs, DMFs) and grant applications.
isoSolutions also offers an extensive catalog of radiochemicals, radiopharmaceuticals, in-vivo cold kits, stable isotopes, labeled compounds, reagents, shipping containers, laboratory equipment and calibration sources from high quality, reliable suppliers. With isoSolutions, customers can obtain a one-stop shopping service as well as technical support.
David T. Drummond, Managing Director of isoSolutions, states, “We are looking forward to welcoming our customers from North America, South America, China and elsewhere to our booth #1336 at the SNNMI exhibition. We are especially proud that this international congress is being held in our hometown of Vancouver.”